[Aftermath of Drug Price Reform] ② Pharmaceutical Companies in Crisis, Struggling with 'Product Portfolio Diet'
Managing New Drug Pipelines with a Focus on Profitability
Consensus Grows on the Need for Changes in Structures Like CSOs and Contract Manufacturing
Calls for Safeguards During Industry Transition Grow Louder
①Shaken Laboratories, Departing Talent
②Pharmaceutical Companies Facing Urgency, Struggling with 'Product Line Diet'
③Unclear Preferential Criteria Hamper Business Planning
Amid the government's drug price reform, small and medium-sized pharmaceutical companies with a high reliance on generics are accelerating their efforts to fundamentally reassess their R&D and production portfolios. Generics, which are expected to become less profitable, are seeing delayed approval applications, while late-stage clinical candidates with high costs are increasingly being considered for technology transfer or joint development rather than in-house advancement.
A prime example is Company A, which recently streamlined its pipeline of cardiovascular disease treatments. This company had previously managed several promising candidates, confirmed for efficacy and commercial viability in early clinical trials, as in-house development prospects. Internally, there were expectations that taking these candidates through Phase 3 trials could lead to the creation of domestic new drugs. However, following the drug price reform, the company concluded that a decline in generic sales would make it difficult to cover hundreds of millions of won in late-stage clinical costs. As a result, it shifted its strategy from in-house commercialization to technology transfer. An insider familiar with the situation commented on July 1, "If we could proceed through commercialization, we might have launched more new drugs, but since it is hard to secure enough funding for Phase 3 trials, we have decided to abandon several promising pipelines."
Industry Reorganizing Product Lines Based on Profitability
Some companies are recalculating expected drug prices, development costs, approval timelines, and market entry orders for new generics and data-submission drugs. Ingredients with small market sizes or intense competition are being deprioritized. A development manager at a medium-sized pharmaceutical company said, "We are now sorting which products can remain profitable after the drug price reform and which ones need to be withdrawn. It is no longer sustainable to simply increase the number of products."
According to the Health Insurance Review & Assessment Service, the domestic market for generics and original drugs with generics in 2024 was about 19.49 trillion won, accounting for 72.4% of total drug expenditures. Out of all reimbursed drugs, 19,120 are generics, representing 80% of the total. Notably, among the top 20 ingredients with the highest drug expenditures, the average period for generic listing was 16.2 years, and each ingredient had an average of over 83.4 products.
In this environment, as drug prices fall, managing the profitability of each product becomes critical. The fixed costs required to maintain a single product—including bioequivalence tests, registration of active pharmaceutical ingredients, and production process validation—may exceed revenue. This is why the 'product line diet,' or voluntarily withdrawing low-performing items, is spreading industry-wide.
Large pharmaceutical companies are planning to offset the impact of price cuts by qualifying as innovative or semi-innovative pharmaceutical companies. In contrast, small companies that have relied on generic sales without their own new drugs or improved drugs find it difficult to quickly boost their R&D investment and quality management capabilities to join the preferential track. A drop in cash flow due to price cuts also makes it harder to increase R&D spending. An industry representative commented, "There is consensus that pharmaceutical companies should reinvest profits into R&D and production rather than sales, but for those dependent solely on generics, this transition will be particularly burdensome."
Industry Concerns Materialize Ahead of Reform Announcement
This industry movement demonstrates that the industrial challenges raised at the early stage of the drug price reform debate are now becoming reality. In an emergency survey conducted late last year by the Korea Pharmaceutical and Bio-Pharma Manufacturers Association's Drug Price System Reform Emergency Committee, targeting CEOs, the industry believed that drug price cuts would not simply lead to reduced sales. There were worries that declining generic sales—which have been the source of funding for developing new products, investing in improved drugs, and expanding production facilities—would also shrink these investments.
Companies responding to the survey anticipated that if the generic drug price was reduced to 40%, R&D and facility investment costs would fall by 25.3% and 32.0%, respectively. Additionally, 74.6% (44 companies) indicated they would fully or partially cancel, change, or postpone generic drug launches. Although the assumed price cut rate differed from the finalized plan, it was clear what the industry feared most: if product profitability is undermined, companies will inevitably prioritize cash preservation over new investments.
While reducing the oversupply of generics and eliminating low-profit products is seen as unavoidable, issues like reliance on contract sales organizations (CSOs) and the low entry barriers from contract manufacturing are being identified as areas in need of improvement. There is also consensus that the market should be reorganized around companies with strong quality and R&D capabilities.
However, there are growing calls for safeguards to ensure that restructuring does not result in an overall reduction in industry investment. If the elimination of low-profit products leads to discontinued development, a reduction in R&D personnel, and a weakened production base, the policy objective of improving the industry's structural soundness may be undermined. At the time of the reform announcement, the emergency committee noted, "To prevent the drug price reduction policy from weakening the industry's innovation engine—such as by shrinking R&D investment—and damaging the industrial ecosystem, the government needs to adopt a flexible policy that considers public health, insurance finances, and industrial competitiveness as a whole."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.